OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Virology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Transmission patterns of hepatitis E virus	99
Colonization of peripheral ganglia by herpes simplex virus type 1 and 2	96
Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19	86
Hepatitis-B virus: replication cycle, targets, and antiviral approaches	74
Editorial Board	72
Inhaled aerosol viral-vectored vaccines against tuberculosis	66
The enigmatic roles of Anelloviridae and Redondoviridae in humans	62
Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy	61
Editorial Board	57
Human placental models for studying viral infections	50
Structural basis for neutralization of enterovirus	49
Virus–host protein interactions as footprints of human cytomegalovirus replication	49
Editorial overview: Viral pathogenesis	47
Viral–host interactions during splicing and nuclear export of influenza virus mRNAs	45
Emerging technologies in the study of the virome	43
New preventive strategies for respiratory syncytial virus infection in children	42
Recent progress in development of monoclonal antibodies against human cytomegalovirus	42
The two faces of oligoadenylate synthetase-like: effective antiviral protein and negative regulator of innate immunity	40
Paramyxoviruses from bats: changes in receptor specificity and their role in host adaptation	36
Editorial Board	36
Shopping for phages? Unpacking design rules for therapeutic phage cocktails	33
Engineering therapeutic phages for enhanced antibacterial efficacy	32
Mitigation of evolved bacterial resistance to phage therapy	31
A complex immune communication between eicosanoids and pulmonary macrophages	30
Perspective on taxonomic classification of uncultivated viruses	30

The enigma of picobirnaviruses: viruses of animals, fungi, or bacteria?	29
A review of broadly protective monoclonal antibodies to treat Ebola virus disease	29
Platelets in the pathogenesis of flavivirus disease	29
Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome: challenges and opportunities	28
Epigenetic control of the Epstein-Barr lifecycle	28
When good turns bad: how viruses exploit innate immunity factors	27
Human organoid models to study coronavirus infections of the respiratory tract	27
Asymmetry in icosahedral viruses	26
Editorial Board	26
Hemagglutinin stability as a key determinant of influenza A virus transmission via air	26
Retasking of canonical antiviral factors into proviral effectors	25
Tissue-resident memory T cells in protective immunity to influenza virus	25
Role of mucosal-associated invariant T cells in coronavirus disease 2019 vaccine immunogenicity	25
Oncogenic Animal Herpesviruses	24
Does arbovirus emergence in humans require adaptation to domestic mosquitoes?	24
Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity	23
Modeling zoonotic and vector-borne viruses	23
Role of the viral polymerase during adaptation of influenza A viruses to new hosts	23
MEK inhibitors as novel host-targeted antivirals with a dual-benefit mode of action against hyperinflammatory respiratory viral diseases	23
State-of-the-art in oncolytic virotherapy using adenoviruses other than the commonly applied adenovirus type 5	23
MicroRNA-mediated control of Epstein–Barr virus infection and potential diagnostic and therapeutic implications	22
Diagnosis and monitoring of virus-associated cancer using cell-free DNA	21
Nucleoside analogs for management of respiratory virus infections: mechanism of action and clinical efficacy	21
Immune responses to human respiratory coronaviruses infection in mouse models	21
Deimmunization of flagellin adjuvant for clinical application	21